[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100185369":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":10,"locations":22,"responsibleParty":92,"collaborators":10,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":10,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":10,"enrollmentInfo":103,"targetDuration":10,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":114,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Janssen Korea, Ltd., Korea","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Fentanyl matrix",null,[12],"Drug: Fentanyl matrix",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":10},"DRUG","Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.",[9],[19],{"name":20,"affiliation":5,"role":21},"Janssen Korea, Ltd., Korea Clinical Trial","STUDY_DIRECTOR",[23,32,39,46,53,60,67,74,76,78,85],{"facility":10,"status":10,"city":24,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"Andong","South Korea",{"type":27,"coordinates":28},"Point",[29,30],128.72275,36.56636,{"lat":30,"lon":29},{"facility":10,"status":10,"city":33,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":34,"geoPoint":38,"contacts":10},"Busan",{"type":27,"coordinates":35},[36,37],129.03004,35.10168,{"lat":37,"lon":36},{"facility":10,"status":10,"city":40,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":41,"geoPoint":45,"contacts":10},"Daegu",{"type":27,"coordinates":42},[43,44],128.59111,35.87028,{"lat":44,"lon":43},{"facility":10,"status":10,"city":47,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"Daejeon",{"type":27,"coordinates":49},[50,51],127.38493,36.34913,{"lat":51,"lon":50},{"facility":10,"status":10,"city":54,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Goyang",{"type":27,"coordinates":56},[57,58],127.19731,36.21689,{"lat":58,"lon":57},{"facility":10,"status":10,"city":61,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":62,"geoPoint":66,"contacts":10},"Incheon",{"type":27,"coordinates":63},[64,65],126.70515,37.45646,{"lat":65,"lon":64},{"facility":10,"status":10,"city":68,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Jeonju",{"type":27,"coordinates":70},[71,72],127.14889,35.82194,{"lat":72,"lon":71},{"facility":10,"status":10,"city":75,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Kwangiu",{"facility":10,"status":10,"city":77,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Kwanju",{"facility":10,"status":10,"city":79,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Seoul",{"type":27,"coordinates":81},[82,83],126.9784,37.566,{"lat":83,"lon":82},{"facility":10,"status":10,"city":86,"state":10,"zip":10,"country":25,"countryCode":10,"cosmosGeoPoint":87,"geoPoint":91,"contacts":10},"Wŏnju",{"type":27,"coordinates":88},[89,90],127.94528,37.35139,{"lat":90,"lon":89},{"type":93,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100185369","the-effectiveness-and-tolerability-of-fentanyl-matrix-in-chronic-non-cancer-pain-assessment-of-patients-pain-treatment-goal-achievement-100185369",false,"NCT01688583","The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement","The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement: Multicenter, Prospective, Open-label, Observational Study","Inclusion Criteria:\n\n* Complain of chronic non-cancer pain that persists for \\>= 3 months\n* Pain inadequately controlled by previous treatment with narcotic analgesics (opium or opium-like compounds with potent analgesic effects, eg, tramadol, codeine, morphine, oxycodone)\n* Women must be postmenopausal, surgically sterile, abstinent, or practicing an effective method of birth control if they have childbearing potential\n* Male patients who agree to use a method of birth control and not to donate sperm for 1 month after the last dose of the study drug\n* A written informed consent for study participation\n\nExclusion Criteria:\n\n* Experience of treatment with Fentanyl matrix within the past 4 weeks\n* No previous experience of use of narcotic analgesics\n* Past or current history of alcohol or drug abuse\n* Cannot use transdermal analgesics due to skin disorder\n* Have serious psychiatric disorder and cannot complete overall study procedures and questionnaire in the judgment of the investigator","ALL","20 Years",{"count":104,"type":105},410,"ACTUAL","OBSERVATIONAL","The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix in chronic non-cancer pain.",[109],"Chronic Pain",[111,112,9,113],"Chronic pain","Chronic non-cancer pain","Transdermal system","COMPLETED","2013-11-20",{"date":117,"type":118},"2013-11-21","ESTIMATED",{"date":120,"type":10},"2011-12",{"date":122,"type":105},"2013-03",{"name":5,"class":6},11]